Skip to main content

Posts tagged with "Drug Development"

  • Business and Markets

    More From Hua – A Change of Business Plans?

    You may remember the mention of Hua Pharmaceuticals here back in August, and the follow-up with details from the company. They’re trying to in-license drugs from other companies and get them approved as quickly as possible in China. The original C&E News article made them sound wildly ambitious, while the company’s own information… Read More
  • Aging and Lifespan

    The Sirtuin Saga

    Science has a long article detailing the problems that have developed over the last few years in the whole siturin story. That’s a process that I’ve been following here as well (scrolling through this category archive will give you the tale), but this is a different, more personality-driven take. The mess is big enough to… Read More
  • Drug Development

    Drugs, Airplanes, and Radios

    Wavefunction has a good post in response to this article, which speculates “If we designed airplanes the way we design drugs. . .” I think the original article is worth reading, but some – perhaps many – of its points are arguable. For example: Every drug that fails in a clinical trial or after it… Read More
  • Drug Assays

    Riding to the Rescue of Rhodanines

    There’s a new paper coming to the defense of rhodanines, a class of compound that has been described as “polluting the scientific literature”. Industrial drug discovery people tend to look down on them, but they show up a lot, for sure. This new paper starts off sounding like a call to arms for rhodanine fans… Read More
  • Cardiovascular Disease

    Pushing Onwards with CETP: The Big Money and the Big Risks

    Remember torcetrapib? Pfizer always will. The late Phase III failure of that CETP inhibitor wiped out their chances for an even bigger HDL-raising follow-up to LDL-lowering Lipitor, the world’s biggest drug, and changed the future of the company in ways that are still being played out. But CETP inhibition still makes sense, biochemically. And… Read More
  • Drug Development

  • Academia (vs. Industry)

    Francis Collins Speaks

    With all the recent talk about the NIH’s translational research efforts, and the controversy about their drug screening efforts, this seems like a good time to note this interview with Francis Collins over at BioCentury TV. (It’s currently the lead video, but you’ll be able to find it in their “Show Guide” afterwards a… Read More
  • Drug Development

    A Note to Andy Grove

    Readers will recall my occasional pieces on Intel legend Andy Grove’s idea for drug discovery. (The first one wasn’t too complimentary; the second was a bit more neutral). You always wonder, when you have a blog, if the people you’re writing about have a chance to see what you’ve said – well, in this case… Read More
  • Drug Development

    Harvard to the Rescue

    Harvard is announcing a big initiative in systems biology, which is an interdisciplinary opportunity if there ever was one. The Initiative in Systems Pharmacology is a signature component of the HMS Program in Translational Science and Therapeutics. There are two broad goals: first, to increase significantly our knowledge of human disease mechanism… Read More
  • Cancer

    Too Many Cancer Drugs? Too Few? About Right?

    According to Bruce Booth (@LifeSciVC on Twitter), Ernst & Young have estimated the proportion of drugs in the clinic in the US that are targeting cancer. Anyone want to pause for a moment to make a mental estimate of their own? Well, I can tell you that I was a bit low. The E&Y number… Read More